Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of liver diseases and viral infections. The primary purpose of Aligos is to leverage its advanced oligonucleotide and small molecule platforms to discover and develop treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) infections. Aligos's pipeline includes various drug candidates in different stages of development, emphasizing innovative solutions aimed at addressing unmet medical needs in these areas. This company's work is critical within the biotechnology and healthcare sectors, significantly contributing to advancements in therapeutic approaches for challenging liver conditions. Aligos Therapeutics holds a key position within the biopharmaceutical market by pushing the boundaries of what's possible in disease treatment through its cutting-edge research and development initiatives.